Published in Medical Letter on the CDC and FDA, January 9th, 2005
Earlier, clearance was received for the use of NT-proBNP in the diagnosis of individuals suspected of having congestive heart failure. The fully automated test is available for use on the Dimension instruments with Heterogeneous Immunoassay Module.
"The availability of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.